Followers | 177 |
Posts | 24528 |
Boards Moderated | 13 |
Alias Born | 04/03/2002 |
Wednesday, September 15, 2021 3:13:34 PM
TRACON Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on Monday, September 20, 2021 at 1:15pm Eastern Time.
To access a live webcast or replay of the presentation, please visit the “Events and Presentations” page within the “Investors” section of the TRACON Pharmaceuticals website at http://www.traconpharma.com.
About TRACON
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at http://www.traconpharma.com.
Company Contact:
Investor Contact:
Mark Wiggins
Brian Ritchie
Chief Business Officer
LifeSci Advisors LLC
(858) 251-3492
(212) 915-2578
mwiggins@traconpharma.com
britchie@lifesciadvisors.com
Recent TCON News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 09:00:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:05:17 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 09:00:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 12:00:12 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/07/2024 10:03:57 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2024 10:00:35 PM
- TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024 • GlobeNewswire Inc. • 02/28/2024 09:02:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:31:59 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/09/2024 09:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 10:00:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 10:00:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 01:05:40 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:00:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2023 09:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 12:10:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:11:15 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 09:01:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:12:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/07/2023 09:02:56 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 07/25/2023 09:19:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2023 12:08:13 PM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM